Tamoxifen response in breast cancer predicted by protein marker
the ONA take:
An abnormally low amount of the protein TGFBR2 is associated with resistance to tamoxifen response in breast cancer treatment, according to a study published in Cancer Research.
“Our data indicate that TGFBR2, which detects TGF-beta and thereby activates subsequent cellular responses, could be used as a marker in the clinics to identify patient subgroups that may not benefit from hormone therapy alone and may require additional therapies,” said author Susann Busch, PhD, of Gothenburg University.
Dr. Busch and colleagues analyzed tumor samples of 564 pre-menopausal women who were enrolled in clinical trials from 1986 to 1991 and randomly assigned to either tamoxifen for two years (276) or no systemic treatment (288).
They found that among women who received tamoxifen and had estrogen receptor-positive tumors, those who had low TGFBR2 levels had a 73 percent lower recurrence-free survival rate compared to those with high levels of the protein.
In a follow-up series of laboratory experiments, the same researchers found that, in a drug-resistant cell line, there were low levels of TGFBR2 and abnormal pathway activation.
An abnormally low amount of the protein TGFBR2 is associated with resistance to tamoxifen response in breast cancer treatment.
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
- Hydroxyurea May Improve Kidney Function in PV-Associated Nephrotic Syndrome
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Study Identifies Factors Associated With Infection-related Complications in ALL
- Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment
- New Recommendations for Secondary Prevention of Cervical Cancer
- Nonadherence to Posttreatment Imaging Follow-up Common Among Breast Cancer Survivors
- HIIT Improves Cardiorespiratory Fitness in Patients With Resectable NSCLC
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|